Plain-English translation of NCT03481283 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are investigating whether amylin, a protein produced by the pancreas in people with type 2 diabetes, plays a role in causing nerve damage in the hands and feet. This study will collect blood samples, skin biopsies, and measure nerve function in people with type 2 diabetes and nerve damage to see if amylin buildup is connected to how severe the nerve problems are.
Nerve damage from diabetes affects millions of people, but doctors don't fully understand why it happens or how to predict who will develop it. This research aims to identify whether amylin could be an early warning sign of nerve damage, which might help doctors detect and treat the problem sooner.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic for testing that includes blood work, a small skin biopsy (a tiny sample of skin), nerve conduction velocity tests (which measure how well your nerves send signals), and a clinical exam to check your nerve sensation. The visit should take a few hours, and you would provide these samples once to help researchers understand the link between amylin and nerve damage.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Enrollment target
~40 participants
Started
February 2018
Primary completion
January 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rani Priyanka Vasireddy, MBBS, MHA
University of Kentucky Department of Neurology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.